Recent Investment Analysts’ Ratings Changes for Amgen (AMGN)

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 8/14/2026 – Amgen had its price target raised by Barclays PLC from $360.00 to $380.00. They now have an “equal weight” rating on the stock.
• 8/10/2026 – Amgen had its price target raised by Guggenheim from $343.00 to $388.00. They now have a “neutral” rating on the stock.
• 8/8/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Amgen had its price target raised by Citigroup Inc. from $345.00 to $405.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Amgen was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/6/2026 – Amgen had its price target raised by Sanford C. Bernstein from $335.00 to $345.00. They now have a “market perform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by UBS Group AG from $420.00 to $440.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by TD Cowen from $420.00 to $452.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have a “sector outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Truist Financial Corporation from $340.00 to $362.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Oppenheimer Holdings, Inc. from $400.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Morgan Stanley from $333.00 to $351.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Royal Bank Of Canada from $370.00 to $400.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Robert W. Baird from $215.00 to $230.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Bank of America Corporation from $312.00 to $317.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Wells Fargo & Company from $390.00 to $400.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by BMO Capital Markets from $400.00 to $450.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Amgen had its price target raised by Barclays PLC from $350.00 to $360.00. They now have an “equal weight” rating on the stock.
• 7/15/2026 – Amgen was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 7/13/2026 – Amgen had its price target raised by UBS Group AG from $400.00 to $420.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Amgen had its price target raised by Guggenheim from $340.00 to $343.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Amgen had its price target lowered by Morgan Stanley from $340.00 to $333.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Amgen had its price target raised by Truist Financial Corporation from $327.00 to $340.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
• 7/1/2026 – Amgen had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $400.00 price target on the stock.
• 6/27/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/18/2026 – Amgen had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 6/18/2026 – Amgen had its “positive” rating reaffirmed by Royal Bank Of Canada.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.